Relief from the COVID-19 Pandemic
preventing laboratory-confirmed COVID-19 illness in people who had no evidence of prior infection two weeks after receiving the vaccine.
Moderna COVID-19 vaccine, and the Johnson & Johnson Janssen COVID-19 vaccine. The Pfizer-BioNTech vaccine and Moderna vaccine are Messenger RNA (mRNA) vaccines. The mRNA is genetically engineered allowing cells to create a piece of S protein found on the surface of the COVID-19 virus. The body will begin to replicate the S protein throughout cells, which causes the body to generate antibodies. Even if a vaccinated individual does contract the COVID-19 virus, the antibodies present from the vaccine will fight the virus. The COVID-19 Pfizer-BioNTech vaccine is a two-part series vaccine, which is showing efficiency of 95 percent with preventing COVID-19 infection after administration. The two-part series of the Moderna vaccine is 94.1 percent effective at preventing infection and symptoms after the second dose. Since both vaccinations are mRNA vaccinations, it is best to choose whichever is available when making an appointment for the vaccine. Those vaccinated with the PfizerBioNTech or Moderna COVID-19 vaccine are considered protected within two weeks after the second dose of the vaccine. The Johnson & Johnson Janssen COVID-19 vaccine falls into the vector vaccine category. Viral vector vaccines use modified versions of different viruses as a vector. The vector acts as a transport for the vaccine, delivering instructions to our cells in the form of genetic material (a gene). The vaccine does not cause infection with COVID-19
Heritage Publishing, Inc. © 2021
or the virus that is used as the vector. The vaccine causes the cells to make copies of the S protein and transmit them to the surfaces. Then antibodies are created to fight the virus if it is contracted. The Johnson & Johnson Janssen COVID-19 vaccine is a single-dose vaccination and protection
“ The vaccine can help limit the risk of developing serious or deadly symptoms. ”
In April 2021, the CDC stated that the Johnson & Johnson Janssen COVID-19 vaccine had more than 6.8 million doses administered in the United States. Also in April, the Johnson & Johnson Janssen COVID-19 vaccine was recalled after six reported cases of a rare and severe type of blood clot occurred after individuals received this vaccine. The reports of this condition have been only women under the age of 50. “In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia),” said the CDC. “These particular events seem to be extremely rare. COVID-19 vaccine safety is a top priority for the federal government, and we take all reports of health problems following the COVID-19 vaccination very seriously. People who have received the Johnson & Johnson Janssen COVID-19 vaccine who develop a severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider,” stated the CDC.
Benefits of Vaccination from the vaccine will begin 28 days after the dose is administered. According to the CDC, the single-dose Johnson & Johnson Janssen COVID-19 vaccine was 66.3 percent effective in clinical trials with
“The COVID-19 vaccine is a sign of hope and might restore a sense of normalcy. So many people remain steadfast in their efforts to stay safe and are so appreciative of the vaccine. We’ve vaccinated thousands already, and have vaccinated as much as
7
